News

The study of human pluripotent stem cells, which can develop into any cell type in the body, is providing Weill Cornell Medicine and NewYork-Presbyterian investigators with new insights into the virus that causes COVID-19 and how it may infect organs such as the pancreas and liver.

A code discovered in DNA packaging proteins enables the rapid expression of genes needed to fight immediate threats, a finding that may pave the way for new treatments for cancer and inflammatory diseases.

Medical students at Weill Cornell Medicine-Qatar (WCM-Q) have answered a call from the Ministry of Public Health (MOPH) for volunteers to help tackle the COVID-19 pandemic.

With cases of COVID-19 spiking in many areas of the United States, and a greater resurgence expected in the fall, whether and how to reopen schools is the subject of strong national interest.

Researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have published guidance on how physicians working on the front lines of the COVID-19 pandemic can compassionately inform family members of the painful news that their loved one has died.

A team of scientists from Weill Cornell Medicine and Texas A&M University has identified a tuberculosis (TB) protein that future drugs might be able to target, with minimal side-effects compared to current treatments—potentially a critical discovery given the global public health crisis of drug-resistant TB.

COVID-19 patients have a higher risk of stroke than patients with influenza, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

An understudied type of liver cell may drive scarring in liver disease and could be a promising target for new treatments, suggests a new study by Weill Cornell Medicine investigators.

An enzyme has been discovered to play a critical role in blocking the metabolic processes that contribute to the rapid growth and spread of liver cancer, according to a new study by Weill Cornell Medicine researchers.

The hormonal shifts that occur with menopause can increase the risk of brain changes associated with Alzheimer’s disease, according to new research from Weill Cornell Medicine investigators.

A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.

Epidemiological models of COVID-19 that are used to guide policies on social distancing measures should take into account the special dynamics of the coronavirus’s spread in nursing homes and other long-term care (LTC) facilities.

Critical care physicians, infectious disease specialists and pulmonologists from Weill Cornell Medicine and NewYork-Presbyterian have published a clinical practice guide for managing severe COVID-19 in the New England Journal of Medicine.

Dr. Jim Hu, the Ronald P. Lynch Professor of Urologic Oncology at Weill Cornell Medicine, has been awarded more than $7 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for two studies on outcomes of prostate cancer biopsy and treatment.

Three proteins bind to chemical marks on molecular messages in cells, targeting the messages for degradation, according to researchers at Weill Cornell Medicine. The results overturn some prevailing models of how cells use chemical tags to control their genes' expression and may offer new targets for treating leukemia, which can arise when the chemical tags go awry.

An intensive, one-year, lifestyle-modification treatment for type 2 diabetes patients, featuring a low-calorie diet and physical exercise, resulted in a large average weight loss, and remission of diabetes for most patients, in a clinical trial led by researchers at Weill Cornell Medicine-Qatar.

In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.

A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).

A triple combination of an investigational drug that enables immune cells to infiltrate tumors, an immunotherapy drug and chemotherapy showed promising responses in patients with the most common type of metastatic pancreatic cancer, according to data from an international phase 2a clinical trial led by Weill Cornell Medicine and Beth Israel Deaconness Medical Center investigators.